The leukotriene receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Leukotriene Receptors [31, 34]) are activated by the endogenous ligands leukotrienes (LT), synthesized from lipoxygenase metabolism of arachidonic acid. The human BLT 1 receptor is the high affinity LTB 4 receptor whereas the BLT 2 receptor in addition to being a low-affinity LTB 4 receptor also binds several other lipoxygenase-products, such as 12S-HETE, 12S-HPETE, 15S-HETE, and the thromboxane synthase product 12-hydroxyheptadecatrienoic acid. The BLT receptors mediate chemotaxis and immunomodulation in several leukocyte populations and are in addition expressed on non-myeloid cells, such as vascular smooth muscle and endothelial cells. In addition to BLT receptors, LTB 4 has been reported to bind to the peroxisome proliferator activated receptor (PPAR) α [ 189] and the vanilloid TRPV1 ligand-gated nonselective cation channel [210] . The receptors for the cysteinylleukotrienes (i.e. LTC 4 , LTD 4 and LTE 4 ) are termed CysLT 1 and CysLT 2 and exhibit distinct expression patterns in human tissues, mediating for example smooth muscle cell contraction, regulation of vascular permeability, and leukocyte activation. There is also evidence in the literature for additional CysLT receptor subtypes, derived from functional in vitro studies, radioligand binding and in mice lacking both CysLT 1 and CysLT 2 receptors [34]. Cysteinyl-leukotrienes have also been suggested to signal through the P2Y 12 receptor [91, 236, 265], GPR17 [53] and GPR99 [161].

